Metagenomi (MGX) to Release Earnings on Wednesday

Metagenomi (NASDAQ:MGX) is projected to announce its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.6059) per share and revenue of $7.3270 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Metagenomi (NASDAQ:MGX) last posted its earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.02). Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%.The business had revenue of $3.91 million for the quarter, compared to analyst estimates of $7.33 million. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Stock Down 4.2%

NASDAQ:MGX opened at $1.37 on Wednesday. Metagenomi has a 52 week low of $1.23 and a 52 week high of $3.95. The stock’s fifty day moving average is $1.54 and its two-hundred day moving average is $1.90. The company has a market capitalization of $51.54 million, a P/E ratio of -0.58 and a beta of 0.45.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MGX. Weiss Ratings reissued a “sell (d-)” rating on shares of Metagenomi in a research report on Monday, December 22nd. Wall Street Zen cut shares of Metagenomi from a “hold” rating to a “sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Hedge Funds Weigh In On Metagenomi

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd raised its holdings in Metagenomi by 353.4% in the fourth quarter. XTX Topco Ltd now owns 68,994 shares of the company’s stock valued at $112,000 after acquiring an additional 53,778 shares in the last quarter. Quadrature Capital Ltd purchased a new position in Metagenomi in the fourth quarter worth approximately $55,000. Bridgeway Capital Management LLC grew its holdings in Metagenomi by 102.1% during the 4th quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after acquiring an additional 200,000 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of Metagenomi in the 4th quarter valued at approximately $53,000. Finally, Wells Fargo & Company MN increased its position in shares of Metagenomi by 16.1% in the 4th quarter. Wells Fargo & Company MN now owns 118,410 shares of the company’s stock valued at $192,000 after purchasing an additional 16,402 shares during the last quarter.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.